Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 14/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.60 |
| ▸ | HPN | P05981 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.60 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | CD69 | Q07108 | 2/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5576330 | 0.89 | VCAM1 (0.58) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL13609380 | 0.89 | VCAM1 (0.63) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL14308977 | 0.88 | VCAM1 (0.60) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL14037559 | 0.86 | VCAM1 (0.70) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL5574105 | 0.85 | VCAM1 (0.57) | VCAM1ALOX15HPNMAPTSIRT5 | |
| Elsibucol SCHEMBL6002307 | 0.85 | VCAM1 (0.73) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL14417961 | 0.85 | VCAM1 (0.60) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL5573386 | 0.84 | VCAM1 (0.61) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL5574398 | 0.84 | VCAM1 (0.61) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL12042623 | 0.83 | VCAM1 (0.55) | VCAM1ALOX15HPNMAPTSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008053374-A2 | TOPICALLY APPLIED PROBUCOL-CONTAINING AGENT WITH PROTECTIVE AND REGENERATIVE EFFECT | NEUDECKER BIRGIT (DE) | 2008-05-08 | — | — | WO | claimed |
| US-20080019957-A1 | TOPICALLY APPLIED PROBUCOL-CONTAINING AGENT WITH PROTECTIVE AND REGENERATIVE EFFECT | NEUDECKER BIRGIT | 2008-01-24 | — | — | US | claimed |
| EP-4735446-A1 | SALTS AND SOLID FORMS OF A COMPOUND THAT MODULATES IRAK4 | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260035374-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250312396-A1 | Control of Cellular Redox Levels | MCKENNA ELIZABETH (US) | 2025-10-09 | — | — | US | disclosed |
| US-12415808-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20070213303-A1 | Methods for reducing platelet activation and for the treatment of thrombotic events | CRABTREE ACQUISITION CO, LLC | 2007-09-13 | — | — | US | disclosed |
| WO-2007044726-A2 | METHODS FOR REDUCING PLATELET ACTIVATION AND FOR THE TREATMENT OF THROMBOTIC EVENTS | ATHEROGENICS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20060020038-A1 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | CRABTREE ACQUISITION CO, LLC | 2006-01-26 | — | — | US | disclosed |
| WO-2006007508-A2 | COMPOUNDS AND METHODS FOR TREATING DIABETIC VASCULAR DISEASES | ATHEROGENICS, INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005112914-A2 | PHENOLIC ANTIOXIDANTS FOR THE TREATMENT OF DISORDERS INCLUDING ARTHRITIS, ASTHMA AND CORONARY ARTERY DISEASE | ATHEROGENICS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-6960683-B2 | Salt forms of poorly soluble probucol esters and ethers | ATHEROGENICS, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20040082807-A1 | Novel salt forms of poorly soluble probucol esters and ethers | CRABTREE ACQUISITION CO, LLC | 2004-04-29 | — | — | US | disclosed |
| US-20030181520-A1 | Methods of reversing and preventing cardiovascular pathologies | ATHEROGENICS, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003039231-A2 | COMPOUNDS AND METHODS FOR TREATING TRANSPLANT REJECTION | ATHEROGENICS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | VCAM1 3807/4885ALOX15 2164/4885HPN 2987/4885 |
| US-20260035374-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | IRAK4, IRAK1, IRAK2 | VCAM1 545/4885ALOX15 1030/4885HPN 3287/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | VCAM1 4601/4885ALOX15 3873/4885HPN 248/4885 |
| US-20030181520-A1 | Methods of reversing and preventing cardiovascular pathologies | TNNT2, TNNI3, TNNC1 | VCAM1 261/4885ALOX15 573/4885HPN 595/4885 |
| US-20070213303-A1 | Methods for reducing platelet activation and for the treatment of thrombotic events | PLAT, F2, TFPI | VCAM1 351/4885ALOX15 193/4885HPN 112/4885 |
| US-20060020038-A1 | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease | MPO, ALOX15B, ALOX12 | VCAM1 961/4885ALOX15 6/4885HPN 2228/4885 |
| US-20080019957-A1 | TOPICALLY APPLIED PROBUCOL-CONTAINING AGENT WITH PROTECTIVE AND REGENERATIVE EFFECT | CUTA, KRT18, EBP | VCAM1 1396/4885ALOX15 1093/4885HPN 824/4885 |
| US-12415808-B2 | Pyrrolo[1,2-b]pyridazine derivatives | CYP11B2, CYP11B1, DHPS | VCAM1 4497/4885ALOX15 251/4885HPN 1580/4885 |
| US-20040082807-A1 | Novel salt forms of poorly soluble probucol esters and ethers | SLC10A1, SLC10A2, CEL | VCAM1 1745/4885ALOX15 488/4885HPN 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.